Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Risankizumab Formulations in Healthy Subjects
NCT06571266Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Sep 2024
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised trial of risankizumab in plaque psoriasis, psoriatic arthritis (PsA), Crohn's disease and 1 more (3 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants with Adverse Events, Maximum Observed Serum Concentration and 6 more. Started Sep 2024; status: completed.
02
Drugs
risankizumab
03
Conditions
plaque psoriasispsoriatic arthritis (PsA)Crohn's diseaseulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06571266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06571266.